G. H. Malek

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.

C. Roehrborn, M. Resnick, S. Kaplan, 1999, Urology.

Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group.

J. Trachtenberg, M. Elhilali, P. Narayan, 1999, Urology.

Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

P. Schellhammer, C. Roehrborn, M. Resnick, 2000, The Journal of urology.

Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy.

D. Kapoor, R. Echols, E. Whalen, 1998, Urology.

Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.

C. Roehrborn, J. Gottesman, B. Saltzman, 2004, The Journal of urology.

Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

P. Schellhammer, C. Roehrborn, M. Resnick, 2000, The Journal of urology.

A multicenter, double-blind, trimethoprim-sulfamethoxazole controlled study of enoxacin in the treatment of patients with complicated urinary tract infections.

S. Finegold, S. Childs, C. Cox, 1989, Journal of Urology.

Single-dose oral ciprofloxacin compared with cefotaxime and placebo for prophylaxis during transurethral surgery.

R. Echols, E. Whalen, S. Kowalsky, 1999, The Journal of antimicrobial chemotherapy.